Hovione has re-joined the membership of the Instituto de Biologia Experimental e Tecnológica (IBET) to “increase the scope and strength of its research and development programs in the areas of novel and high potential pharmaceutical technologies”. The company is responsible for the process development, manufacture, and formulation of small molecules, and during the past six years it was a key technical partner behind 24 of the 273 NDAs FDA approved.
The pandemic has catalysed an acceleration of scientific progress, the company says, outlining the power of novel treatment modalities to fight diseases. The objective of the collaboration is to combine knowledge from both partners to create industrial innovation in these emerging therapeutic fields.
“We are delighted with the return of Hovione to the membership of IBET. Our goal is to strengthen the R&D capabilities of our members, this important partnership with Hovione will allow to pool together complementary scientific competencies and power the development of biopharmaceuticals that are essential to patient health. To win in the area of biologics and novel therapies it is critical to have access to state-of-the art competencies and support technologies” said Paula Alves, CEO, IBET.
“The partnership with IBET opens a new chapter in Hovione's history. We will bring together our knowledge in chemistry, in cutting-edge technologies, of the market and of the FDA regulatory process with IBET’s command of cell biology, viral biology and bioprocessing. If the twentieth century was the century of chemistry, the 21st century is the one of biology. IBET scientists have built deep knowledge in specific areas, we plan to work together to turn that knowledge into industrial innovation” said Guy Villax, CEO of Hovione.
“Hovione was a founding member of iBET and I had the privilege to meet Ivan Villax, a remarkable scientist and entrepreneur open to the world stage where Hovione plays a key role since its foundation. The experience in international collaborations and the complementary competencies that Hovione an IBET have built over the past 25 years in a parallel fashion will now combine in what I expect to be a fruitful collaboration” said Manuel Carrondo, VP, IBET.
